logo
Plus   Neg
Share
Email

Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Medicines Agency's Committee has recommended to extend the approval for Dupixent to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is currently approved for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Regeneron and Sanofi are also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other type 2 inflammation.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>